Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $171.45M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.12M
Average 1.37M
ELDN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Eledon Pharmaceuticals, Inc.NASDAQ: ELDN
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$39.03M, compared with -$6.5M a year earlier. Trailing-twelve-month EBITDA was -$78.03M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -27.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$39.03M-277.7% QoQ
- Last fiscal yearDec 2025
- -$45.27M-27.9% YoY
- LTMMar 2026
- -$78.03M-325.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -500.8% | +100.0% | +600.8 pp |
| 1 year | -27.9% | +100.0% | +127.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (45.27M) USD
- Year-over-year change
- -27.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (45.27M) | -27.9% |
| FY2024 | 2024-12-31 | (35.39M) | +69.5% |
| FY2023 | 2023-12-31 | (116.16M) | -194.8% |
| FY2022 | 2022-12-31 | (39.41M) | -7.5% |
| FY2021 | 2021-12-31 | (36.67M) | — |
EBITDA vs competitors
How ELDN compares with its peers on the latest reported figures
- ELDN's LTM Mar 2026 EBITDA of -$78.03M is the 4th highest of the 11 companies compared; the peer median is -$106.31M.
- Its year-over-year change of -325.2% is the 10th highest of 11, against a peer median of -24.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $73.43M | +298.8% | — | 505.0% | |
| LTM Mar 2026 | $44.91M | -17.8% | +34.6% | 19.8% | |
| LTM Mar 2026 | -$50.86M | -14.6% | — | — | |
| LTM Mar 2026 | -$78.03M | -325.2% | — | — | |
| LTM Mar 2026 | -$79.77M | -33.1% | — | 3956.7% | |
| LTM Mar 2026 | -$100.08M | +56.8% | — | 258.7% | |
| LTM Mar 2026 | -$112.54M | -37.5% | — | 308.4% | |
| LTM Mar 2026 | -$136.24M | -213.5% | — | 62.6% | |
| LTM Mar 2026 | -$160.41M | +32.7% | — | — | |
| LTM Mar 2026 | -$164.87M | -697.5% | — | 2873.3% | |
| LTM Mar 2026 | -$179.89M | -30.1% | — | — | |
| Peer median (excluding ELDN) | -$106.31M | -24.0% | +34.6% | 308.4% | |
Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.74M | 27.08M | 30.31M | 51.96M | 66.27M |
| Selling, General & Admin | 13.13M | 12.7M | 12.69M | 18.61M | 16.98M |
| Operating Expenses | 36.87M | 88.43M | 43M | 70.58M | 83.25M |
| Depreciation & Amortization | 195K | 373K | 374K | 359K | 313K |
| EBITDA | (36.67M) | (39.41M) | (116.16M) | (35.39M) | (45.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (36.87M) | (88.43M) | (43M) | (70.58M) | (83.25M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7K | 462K | (73.54M) | 34.82M | 37.67M |
| Income Before Tax | (36.86M) | (87.97M) | (116.54M) | (35.75M) | (45.58M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (2.35M) | 0 | 0 | 431K | 35K |
| Net Income | (34.51M) | (87.97M) | (116.54M) | (36.18M) | (45.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| EPS (Diluted) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| Weighted Avg Shares | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
| Weighted Avg Shares (Diluted) | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
Intrinsic Alpha fair value
Locked
Current Price
$2.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.